Full cycle of production – from a substance to finished dosage form
Modern equipment and quality control methods
Automation – 90%
Production of active pharmaceutical substances.
After reaching the design capacity the company will be able to cover Russian needs in insulin for 100 % and to expand export opportunities
A leading full-cycle producer of gene-engineering human insulin – from synthesis of a substance to finished dosage form.
The plant can cover 30% of Russian needs in insulin